There is more hope than ever for people with diseases that have so far been incurable or poorly managed by conventional treatments, thanks to Advanced Therapy Medicinal Products (ATMP). VILS has been playing a key role in bringing some of these therapies out of the lab and into patients’ lives. On the cutting-edge of life sciences, these therapies include:

• Gene Therapy
• Cell Therapy  – both modified and unmodified
• Tissue-Engineered Products 

VILS is active in all three of these areas and the associated platforms, always keeping up with scientific developments to know what is on the way. We have an established track record of success with clients on the cutting edge of all three areas due to our understanding of the challenges involved and our experience working on the leading edge of technology. 

First-in-the-world facilities 

Often, we work on the first facilities of their kind in the world. For example, we engineered the world’s first GMP-validated facility for induced pluripotent stem cells (iPSC). We also engineered the first GMP-validated mRNA facility back in 2014. 

To start with, these new therapies require sophisticated manufacturing facilities because they are so complex and ground-breaking. The ATMP industry is also highly regulated due to the risks involved. Regulatory bodies like the EMA (European Medicines Agency) and FDA (Food and Drug Administration) have special frameworks for the approval of these products. The scientists and engineers on our teams have a thorough understanding of these frameworks. 

Process-oriented, aligned with business needs 

That is why our scientists and engineers build around you, your process, your business needs and your regulatory environment as a starting point, not with a predetermined facility that we alter to fit. When it comes to emerging technologies like iPSC and others, for example, we think there is no other practical way forward. The evolution is simply too rapid. 

We also understand the business issues involved and always align our proposals to your growth plan, which is why our concepts and designs have often proved useful to our clients’ business cases when seeking funding. 

Learn more about the VILS approach, which starts from your research and business needs.

As we work together, you will find that we are process, manufacturing, and R&D experts, as well as process architects with practical, hands-on experience. Many of them have worked in your field. The multi-disciplinary team we tailor for you will include specialists in pharma and biotech applications. In short, we not only understand your language, we speak it.